Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan Sells 2,413 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan sold 2,413 shares of the business’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $75.27, for a total transaction of $181,626.51. Following the transaction, the director now directly owns 57,273 shares in the company, valued at approximately $4,310,938.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

John Francis Cogan also recently made the following trade(s):

  • On Monday, March 16th, John Francis Cogan sold 2,413 shares of Gilead Sciences stock. The stock was sold at an average price of $67.26, for a total transaction of $162,298.38.
  • On Monday, March 9th, John Francis Cogan sold 2,413 shares of Gilead Sciences stock. The stock was sold at an average price of $77.97, for a total transaction of $188,141.61.

NASDAQ GILD traded up $2.00 on Thursday, hitting $71.66. 6,776,565 shares of the company were exchanged, compared to its average volume of 30,795,556. The firm has a 50 day moving average of $71.37 and a two-hundred day moving average of $66.57. The company has a market cap of $91.13 billion, a P/E ratio of 17.02, a P/E/G ratio of 5.79 and a beta of 0.99. The company has a current ratio of 3.10, a quick ratio of 3.01 and a debt-to-equity ratio of 1.02. Gilead Sciences, Inc. has a 1-year low of $60.89 and a 1-year high of $85.97.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.67 by ($0.37). The company had revenue of $5.88 billion for the quarter, compared to analyst estimates of $5.74 billion. Gilead Sciences had a return on equity of 35.49% and a net margin of 23.99%. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the company earned $1.44 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 6.03 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.68 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.63. The ex-dividend date is Thursday, March 12th. This represents a $2.72 annualized dividend and a yield of 3.80%. Gilead Sciences’s dividend payout ratio is 44.30%.

A number of equities research analysts have weighed in on the stock. SunTrust Banks reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday. Cowen reiterated a “buy” rating and set a $85.00 price target on shares of Gilead Sciences in a research note on Thursday, January 2nd. Raymond James downgraded shares of Gilead Sciences from a “strong-buy” rating to an “outperform” rating and decreased their price target for the stock from $81.00 to $80.00 in a research note on Wednesday, February 5th. Royal Bank of Canada reiterated a “buy” rating and set a $83.00 price target on shares of Gilead Sciences in a research note on Wednesday. Finally, Barclays assumed coverage on shares of Gilead Sciences in a research note on Thursday, February 27th. They set an “underweight” rating and a $62.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and fifteen have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $78.08.

A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Quadrant Capital Group LLC raised its holdings in Gilead Sciences by 4.7% during the 4th quarter. Quadrant Capital Group LLC now owns 9,193 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 410 shares during the last quarter. Macquarie Group Ltd. raised its holdings in Gilead Sciences by 1.5% during the 4th quarter. Macquarie Group Ltd. now owns 399,336 shares of the biopharmaceutical company’s stock worth $25,948,000 after purchasing an additional 5,806 shares during the last quarter. TFG Advisers LLC bought a new stake in Gilead Sciences during the 4th quarter worth about $413,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Gilead Sciences by 24.1% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 1,530,276 shares of the biopharmaceutical company’s stock worth $99,397,000 after purchasing an additional 297,360 shares during the last quarter. Finally, Engrave Wealth Partners LLC bought a new stake in Gilead Sciences during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 80.32% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: What are popular range trading strategies?

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.